Militia Long/Short Equity ETF
Limited financial coverage for ORR.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The Militia Long/Short Equity ETF, identified by the symbol ORR, is an actively managed investment vehicle designed to achieve capital appreciation. It employs a dual strategy, taking both long and short positions in equities. For its long-term holdings, the fund primarily focuses on stocks in developed markets that are either deemed undervalued or possess substantial growth potential.
- IPO
- 2025
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on ORR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $39.80
- 52W Low
- $30.66
- 50D MA
- $38.55
- 200D MA
- $37.00
- Beta
- 0.03
- RSI (14)
- 54
- Avg Volume
- 56.75K
No earnings-call transcripts are available for ORR yet.
- Free Float
- 0.0%
- Shares Outstanding
- 973.43K
- Float Shares
- 0
of shares held by institutions
35 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Leonard Rickey Investment Advisors P.L.L.C. | 447.13K | ▲ 447.13K |
| Militia Capital Management LLC | 404.41K | ▼ 20.00K |
| Stapp Wealth Management, Pllc | 251.73K | ▲ 4.15K |
| Svrn Asset Management, LLC | 215.74K | ▼ 7.84K |
| Hightower Advisors, LLC | 164.66K | ▲ 3.41K |
| Militia Capital Partners, LP | 161.00K | ▲ 38.00K |
| Jane Street Group, LLC | 110.75K | ▲ 61.39K |
| Citadel Advisors LLC | 110.47K | ▼ 8.83K |
| Arkadios Wealth Advisors | 97.78K | ▲ 97.78K |
| Pensionmark Financial Group, LLC | 81.26K | 0 |
| Gts Securities LLC | 63.82K | ▲ 34.73K |
| Newedge Advisors, LLC | 57.57K | ▼ 111.11K |
Our ORR coverage
Recent articles, reports, and earnings notes.
No research on ORR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORR report →Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
gurufocus.com · Oct 3
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
gurufocus.com · Oct 3
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
gurufocus.com · Sep 13
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
gurufocus.com · Jul 23
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
gurufocus.com · Jun 13
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
gurufocus.com · Jun 13
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
gurufocus.com · Jun 11
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
gurufocus.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.